Understanding and predicting product shelf-life. Dr. Mathias Kramer

Size: px
Start display at page:

Download "Understanding and predicting product shelf-life. Dr. Mathias Kramer"

Transcription

1 Understanding and predicting product shelf-life Dr. Mathias Kramer

2 Purpose of Stability Testing What affects Stability? Evaluation of Stability Data Reasonable Stability Testing Conclusion

3 Purpose of Stability Testing Gather knowledge about the product and degradation Find interactions between excipients and API Investigate different package dresses Enables a product to be registered Establish expiration dating period Establish storage conditions, label claims Establish regulatory specifications derived from a consideration of available stability data Delivers medicines of proven quality, safety and efficacy

4 Purpose of Stability Testing What affects Stability? Evaluation of Stability Data Reasonable Stability Testing Conclusion

5 What affects Stability? (1) Storage Time Storage Condition (Temperature, Humidity, Light, Oxygen) Dosage Form (Tablet, Capsule, Vial) Manufacturing Procedure Packaging Formulation (Composition, Quantity, Quality of excipients and API)

6 What affects Stability? (2) Temperature - the kinetic of a degradation can be described by the Arrhenius equation - for evaluation you need the accelerated condition k=a*exp(-ea/r*t) k: is the rate coefficient; A: is a constant; Ea: is the activation energy R: is the universal gas constant; T: is the temperature (in Kelvin) A historically useful generalization supported by the Arrhenius equation is that, for many common chemical reactions at room temperature, the reaction rate doubles for every 10 degree Celsius increase in temperature

7 What affects Stability? (3) Humidity - may influence degradation; hydrolysis - for evaluation you need different humidity, packaging configuration Light - may influence degradation; photoreaction - for evaluation you need photo stability testing Oxygen - may influence degradation; oxidation - for evaluation you need different packaging configuration

8 What affects Stability? (4) Packaging configuration - no temperature protection - light protection - humidity protection humidity protection (water vapour permeability) of blisters PVC- < Duplex- / Triplex- < Alu- blisters humidity protection (water vapour permeability) of bottles HDPE- bottles < Glass- bottles

9 What affects Stability? (5) Formulation Fixed dose combination finished pharmaceutical product (FDC-FPP) Def.: A finished pharmaceutical product that contains two or more actives - May have an impact on the stability, the APIs may react with each other - The most sensible API will trigger the shelf-life - Testing has to take all APIs into account (assay, degradation, dissolution)

10 Purpose of Stability Testing What affects Stability? Evaluation of Stability Data Reasonable Stability Testing Conclusion

11 Evaluation of Stability Data (1) Defined in the ICH Q1E and WHO-Guideline A systematic evaluation should be performed. Stability data for each attribute should be assessed sequentially The assessment should begin with any significant change at the accelerated condition Extrapolation to extend the shelf life beyond the period covered by long-term data can be proposed if no significant change is observed at the accelerated condition

12 Evaluation of Stability Data (2) Provisional shelf-life may be established without statistical analysis if The API is known to be stable (not easily degradable) 6 month accelerated and 12 month long term data are available The accelerated and long-term data show no or little changes or variability The manufacturer will continue the long-term studies up to the proposed shelflife Results will be submitted to the health authorities

13 Evaluation of Stability Data (3) Significant change 5% change in assay from its initial value Any degradation product exceeding its acceptance criteria Failure to meet the acceptance criteria for appearance, physical attributes and functionality test (e.g. color, phase separation, caking, hardness) Also, as appropriate for the dosage form; - failure to meet the acceptance criteria for ph - failure to meet acceptance criteria for dissolution for 12 dosage units

14 Evaluation of Stability Data (4) Statistical Approach - Regression analysis (linear, non-linear) An appropriate approach to shelf life estimation is to analyze - assay - degradation products Determine the earliest time at which the 95% confidence limit intersects the proposed acceptance criterion

15 Evaluation of Stability Data (5) Proposed shelf life for Room temperature Storage Y= 2 * X but not more than X + 12 (24 month) (30 month) Y= 2 * X but not more than X + 12 (24 month) (30 month) depending on the statistical evaluation Available long-term data [X] X (12 month) (18 month) X (12 month) (18 month) Change or variability over time Available accelerated data Change or variability over time little or no 6 month little or no Showing change and / or variability over time statistical analysis 6 month Showing change and / or variability over time

16 Purpose of Stability Testing What affects Stability? Evaluation of Stability Data Reasonable Stability Testing Conclusion

17 Reasonable Stability Testing (1) What has to be tested? Basis Q1A (R2) Stability studies should include testing of those attributes of the drug product that are susceptible to change during the storage and are likely to influence quality, safety and / or efficacy.

18 Reasonable Stability Testing (2) Galenical Formulation Solid dosage forms (e.g. tablets, capsules) Ampoules Vials Powder, oral suspensions Parameter unlikely to change during storage which could be omitted Identity, Shape und Imprint etc., Uniformity of mass/fill mass/content Identity, extractable volume, sterility, endotoxine test, density Identity, extractable volume, density Identity, Uniformity of mass/content

19 Reasonable Stability Testing (3) Quality Attribute Emulsions Oral Solution and suspensions Aerosols Topical and ophthalmic Smallvolume parenterals Largevolume parenterals Strength Appearance Color Odor a Clarity Moisture + a Dissolution + ph a) + Viscosity + + Resuspendability/redispersiblity + Separation + + Weightloss b) Homogeneity + Particulate/matter/size Extractables + b) + b) Pyrogenicity + + Sterility/microbial limit Preservatives Container closure integrity + Other recommendations c). d) d) e) f) d) d) + May be required or required Not required. a) Required for reconstituted products. b) Required for products in plastic containers c) Heating/cooling cycle 4 C 45 C d) Storage on side or inverted e) Number of metered doses, delivered dose per activation, propellant pressure, valve corrosion, spray pattern, If more than 3.5 g, sample at surface, middle, bottom of container, sample tubes near crimp. [Van den Akker, C. R.; Pharm. md. 53, 483 (1991)]

20 Purpose of Stability Testing What affects Stability? Evaluation of Stability Data Reasonable Stability Testing Conclusion

21 Conclusion You have to take many parameters into account Quality is designed and built into a product and not tested in! Stability has to be planned during lifecycle of the product with standardized conditions

22 Dr. Mathias Kramer Thanks for your attention!

23 We Innovate Healthcare

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

More information

5th Draft ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT. Version 6.0. Update revision : May 2013. Document Control

5th Draft ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT. Version 6.0. Update revision : May 2013. Document Control ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT Version 6.0 Update revision : May 2013 Document Control Version Date 1.0 July 2004 (8 th ACSQ PPWG Meeting; Bangkok) 2.0 February 2005 (9 th ACSQ PPWG

More information

STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

More information

ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products. Step 5

ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products. Step 5 European Medicines Agency August 2003 CPMP/ICH/2736/99 ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products Step 5 NOTE FOR GUIDANCE ON STABILITY TESTING: STABILITY TESTING OF NEW

More information

Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products World Health Organization WHO Technical Report Series, No. 953, 2009 Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of

More information

Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products

Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):892-898 World Health Organization s Guidelines for

More information

STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS

STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS RESTRICTED STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS Discussions are currently ongoing with the WHO Eastern Mediterranean Region towards a synergistic approach in developing a

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) European Medicines Agency Inspections London, 17 December 2003 CPMP/QWP/122/02, rev 1 corr COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING

More information

Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products

Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

ICH Q1A(R2) Guideline. Stability Testing of New Drug Substances and Products

ICH Q1A(R2) Guideline. Stability Testing of New Drug Substances and Products 1.1 ICH Q1A(R2) Guideline Stability Testing of New Drug Substances and Products Comments for its application ICH Q1AR2 C 16 ICH Q1(R2) Stability testing Guidelines: Stability Testing of New Drug Substances

More information

STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW

More information

Guideline on stability testing for applications for variations to a marketing authorisation

Guideline on stability testing for applications for variations to a marketing authorisation 21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications

More information

ICH Topic Q 1 E Evaluation of Stability Data. Step 5 NOTE FOR GUIDANCE ON EVALUATION OF STABILITY DATA (CPMP/ICH/420/02)

ICH Topic Q 1 E Evaluation of Stability Data. Step 5 NOTE FOR GUIDANCE ON EVALUATION OF STABILITY DATA (CPMP/ICH/420/02) European Medicines Agency August 2003 CPMP/ICH/420/02 ICH Topic Q 1 E Evaluation of Stability Data Step 5 NOTE FOR GUIDANCE ON EVALUATION OF STABILITY DATA (CPMP/ICH/420/02) TRANSMISSION TO CPMP February

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

Alharith Hassan. Q 10 Method of Shelf-life estimation. Methods of Chemical stabilisation 11/20/2015

Alharith Hassan. Q 10 Method of Shelf-life estimation. Methods of Chemical stabilisation 11/20/2015 Q 10 Method of Shelf-life estimation Q 10 approach is an old concept that could be useful for estimating the shelf-life at room temperature of products recommended for cold storage. Calculations are based

More information

Implementing an Accelerated Stability Assessment Program: Case Study

Implementing an Accelerated Stability Assessment Program: Case Study Implementing an Accelerated Stability Assessment Program: Case Study Cherokee Hoaglund Hyzer With Special Thanks to Jeff Hofer, Timothy Kramer, Chad Wolfe, Seungyil Yoon, Steve Baertschi and Ken Waterman

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

Evaluating Current Practices in Shelf Life Estimation

Evaluating Current Practices in Shelf Life Estimation Definition of Evaluating Current Practices in Estimation PQRI Stability Working Group Pat Forenzo Novartis James Schwenke Applied Research Consultants, LLC From ICH Q1E An appropriate approach to retest

More information

Manufacturing Services. Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies

Manufacturing Services. Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies Manufacturing Services Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies Bringing ideas to life We built our Swiss pharmaceutical company on one idea born over 70

More information

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY

More information

stability studies in pharmaceutical development Kathy Waddle, MS Wei Pan, Ph.D. RAC Catalent Pharma Solutions

stability studies in pharmaceutical development Kathy Waddle, MS Wei Pan, Ph.D. RAC Catalent Pharma Solutions stability studies in pharmaceutical development Kathy Waddle, MS Wei Pan, Ph.D. RAC Catalent Pharma Solutions Agenda Overview of stability studies during drug product Lifecycle Stability considerations

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Container Closure Systems for Packaging Human Drugs and Biologics CHEMISTRY, MANUFACTURING, AND CONTROLS DOCUMENTATION U.S. Department of Health and Human Services Food and Drug Administration

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS European Medicines Agency Inspections London, 21 June 2006 Doc Ref.: EMEA/CHMP/QWP/49313/2005 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION

More information

SCHEDULE No. 1: Oral solid dosage forms: Fluoroquinolones

SCHEDULE No. 1: Oral solid dosage forms: Fluoroquinolones ANNEX B/ SECTION 8: TECHNICAL SPECIFICATIONS NOTE: The estimated Global need for required below products is provided in Annex H of this ITB. Actual quantity to be ordered in 2015 can vary due to countries

More information

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where

More information

Microbiology and Auditing. Don Singer

Microbiology and Auditing. Don Singer Microbiology and Auditing Don Singer ASQ Northeast Pharmaceutical GMP/Quality Conference 2011 Through the eyes of a Microbiologist Microbiology Audit = Inspection / Investigation Systematic Auditing Planning

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Inspections London, 19 May 2005 CPMP/QWP/4359/03 EMEA/CVMP/205/04 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

More information

How To Test For Leachables

How To Test For Leachables Current FDA Perspective on Leachable Impurities in Parenteral and Ophthalmic Drug products AAPS Workshop on Pharmaceutical Stability Scientific and Regulatory Considerations for Global Drug Development

More information

1.0 Introduction Page 2. 2.0 Scope Page 2. 3.0 General Principles of Shelf-life Studies Page 3. 4.0 Selection of Batches Page 4

1.0 Introduction Page 2. 2.0 Scope Page 2. 3.0 General Principles of Shelf-life Studies Page 3. 4.0 Selection of Batches Page 4 Stability Testing Guideline for Dietary Supplements Final Draft January 2011 Provided by the NSF Stability Testing Working Group Table of Contents 1.0 Introduction Page 2 2.0 Scope Page 2 3.0 General Principles

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES February 2013 RESTRICTED GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES DRAFT FOR COMMENT Should you have any comments on the attached text, please send these to Dr Sabine Kopp, Manager, Medicines

More information

BRIEFING 7 LABELING DEFINITION

BRIEFING 7 LABELING DEFINITION Page 1 of 10 BRIEFING 7 Labeling. This general chapter provides definitions and standards for labeling of official articles. Note that, as with compendial quality standards, labeling requirements also

More information

PHARMACEUTICAL DEVELOPMENT

PHARMACEUTICAL DEVELOPMENT INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step

More information

Annex 6. Guidance on variations to a prequalified product dossier. Preface

Annex 6. Guidance on variations to a prequalified product dossier. Preface Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,

More information

Shelf Life Prediction Of Medical Gloves

Shelf Life Prediction Of Medical Gloves Shelf Life Prediction Of Medical Gloves Presented for the ASTM WG Committee for Medical Glove Expiration Dating Guidance By Uday Karmarkar Akron Rubber Development Laboratory, Inc. ardl@akron.infi.net

More information

Prescription drug products stability and expiration dates*

Prescription drug products stability and expiration dates* Prescription drug products stability and expiration dates* UTMB/NASA-JSC Aerospace Medicine Grand Rounds Houston, TX October 27, 2009 Mansoor A. Khan, R.Ph., Ph.D. Director, FDA/CDER/Division of Product

More information

Overcoming Challenges in the Manufacturing of Pre-Filled Syringes. Farvea, a new comer in the PFS world PFS Tech 2016. June 2016 pharma@fareva.

Overcoming Challenges in the Manufacturing of Pre-Filled Syringes. Farvea, a new comer in the PFS world PFS Tech 2016. June 2016 pharma@fareva. Overcoming Challenges in the Manufacturing of Pre-Filled Syringes Farvea, a new comer in the PFS world PFS Tech 2016 June 2016 pharma@fareva.com Our presence around the world 11 countries 35 sites 12

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE

More information

Introduction to pharmaceutical technology

Introduction to pharmaceutical technology Introduction to pharmaceutical technology Marie Wahlgren Chapter 1 What is the topics of today Introduction to the course Introduction to the project assignment How to choose a new drug formulation 1 Contacts

More information

Workshop A Design Space (DS)

Workshop A Design Space (DS) Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information

More information

GUIDELINES ON STABILITY EVALUATION OF VACCINES

GUIDELINES ON STABILITY EVALUATION OF VACCINES ENGLISH ONLY GUIDELINES ON STABILITY EVALUATION OF VACCINES World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health

More information

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5 European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND

More information

Introduction to Enteris BioPharma

Introduction to Enteris BioPharma Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. European Medicines Agency May 2000 CPMP/ICH/367/96 ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current

More information

3.4 TEST FOR BACTERIAL ENDOTOXINS. Final text for revision of The International Pharmacopoeia

3.4 TEST FOR BACTERIAL ENDOTOXINS. Final text for revision of The International Pharmacopoeia Document QAS/11.5 FINAL July 01 3. TEST FOR BACTERIAL ENDOTOXINS Final text for revision of The International Pharmacopoeia This monograph was adopted at the Forty-sixth WHO Expert Committee on Specifications

More information

Q8(R2): Pharmaceutical Development

Q8(R2): Pharmaceutical Development ICH-GCG ASEAN Q8(R2): Pharmaceutical Development Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference

More information

Guideline on Process Validation

Guideline on Process Validation 1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /

More information

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION I. For Calcium Acetate Drug Products Table I.1 Submission Summary * Drug Product Name Strength(s)

More information

Contract Manufacturing

Contract Manufacturing Contract Manufacturing Connecting Competences. Realizing Ideas. Products, Project Management and Services for the Healthcare Industry Sharing Expertise. System-built solutions As one of the leading companies

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external

More information

PHARMACEUTICAL EXCIPIENTS

PHARMACEUTICAL EXCIPIENTS PHARMACEUTICAL EXCIPIENTS Brian R Matthews PDA Bethesda, MD, USA DHI Publishing, LLC River Grove, IL, USA 10 9 8 7 6 5 4 3 2 1 ISBN: x-xxxxxx-xx-x Copyright 2005 Brian R Matthews. All rights reserved.

More information

P.O.N. RICERCA E COMPETITIVITA' 2007-2013 - Azione II "Interventi di sostegno alla ricerca industriale"

P.O.N. RICERCA E COMPETITIVITA' 2007-2013 - Azione II Interventi di sostegno alla ricerca industriale P.O.N. Ricerca & Competitività 2007-2013 per le Regioni della convergenza Codice Progetto PON01_02464 cofinanziato a valere sull Asse I - Sostegno ai mutamenti strutturali; Obiettivo operativo 4.1.1.1

More information

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009 RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009 This resolution provides for the alteration, inclusion, suspension, reactivation and cancellation after registration of medications and sets forth other provisions.

More information

Guideline on dossier requirements for Type IA and IB notifications

Guideline on dossier requirements for Type IA and IB notifications Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations

More information

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011

More information

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS Overview 6.1 This chapter sets out the Review Committee s findings and recommendations on procurement

More information

Position Classification Standard for Pharmacy Technician Series, GS-0661

Position Classification Standard for Pharmacy Technician Series, GS-0661 Position Classification Standard for Pharmacy Technician Series, GS-0661 Table of Contents SERIES DEFINITION... 2 SERIES COVERAGE... 2 EXCLUSIONS... 4 TITLES... 4 NOTES TO USERS OF THIS STANDARD... 5 CLASSIFICATION

More information

Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen. -Senior Manager Biotechnology-

Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen. -Senior Manager Biotechnology- Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen -Senior Manager Biotechnology- 2005 by West Pharmaceutical Services, Inc., Lionville, PA All rights reserved.

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

Sterilization methods and equipment Lab 1-2

Sterilization methods and equipment Lab 1-2 Sterilization methods and equipment Lab 1-2 PHT 434 Sterilization Sterilization a process that by which all viable M.O are removed or destroyed, based on a probability function. Sterilization concept Sterilization

More information

Oxivir Tb and Accelerated Hydrogen Peroxide (AHP) Frequently Asked Questions

Oxivir Tb and Accelerated Hydrogen Peroxide (AHP) Frequently Asked Questions Oxivir Tb and Accelerated Hydrogen Peroxide (AHP) Frequently Asked Questions What is Accelerated Hydrogen Peroxide (AHP)? AHP is a patented synergistic blend of commonly used, safe ingredients that when

More information

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) 22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:

More information

Guidance for Industry

Guidance for Industry 5 Guidance for Industry Drug Stability Guidelines (This version of the guidance replaces the version that was made available in December 1990. This guidance document has been revised to correct the contact

More information

Drug Stability 75. Drug Stability

Drug Stability 75. Drug Stability Drug Stability 75 Drug Stability Definition: Drug stability means the ability of the pharmaceutical dosage form to maintain the physical, chemical, therapeutic and microbial properties during the time

More information

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING For More Information on Submission of an ANDA in Electronic Common Technical Document (ectd) Format

More information

Industry Implications of Pharmaceutical Quality ICH Guidelines

Industry Implications of Pharmaceutical Quality ICH Guidelines EIPG General Assembly Industry Implications of Pharmaceutical Quality ICH Guidelines 20 th April 2008 Pharmaceutical Quality Develop a harmonised pharmaceutical quality system applicable across the lifecycle

More information

Headin. The Disposal of Medicines in. Nursing Homes. A Guide to Good Practice

Headin. The Disposal of Medicines in. Nursing Homes. A Guide to Good Practice Headin The Disposal of Medicines in g Nursing Homes A Guide to Good Practice Place your message here. For maximum impact, use two or three sentences. November 2011 Contents Page 1.0 Introduction 3 2.0

More information

Table of Contents. List of abbreviations 4. Introduction 5. The history and development of the new guideline ICH Topic Q8 5

Table of Contents. List of abbreviations 4. Introduction 5. The history and development of the new guideline ICH Topic Q8 5 ICH Q8: Pharmaceutical Development. Regulatory Requirements Directed by the New Note for Guidance (EMEA/CHMP/167068/2004) in Comparison to the Previous Guideline (CPMP/QWP/155/96). A Critical View from

More information

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers

Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Tablet Packaging Safety

Tablet Packaging Safety Tablet Packaging Safety Tablet Packaging Safety Gossen Metrawatt supplies controllers which assure minimal temperature deviation even in critical applications. TLT 2600 Packaging Machine at Bayer HealthCare

More information

PERMEABILITY MEASUREMENT

PERMEABILITY MEASUREMENT I. INTRODUCTION PERMEABILITY MEASUREMENT A permeability measurement consists in measuring the flow of gas or vapor through a film or a package. Low permeability values are of great interest for lifetime

More information

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.

More information

Scanning Electron Microscopy Services for Pharmaceutical Manufacturers

Scanning Electron Microscopy Services for Pharmaceutical Manufacturers Scanning Electron Microscopy Services for Pharmaceutical Manufacturers Author: Gary Brake, Marketing Manager Date: August 1, 2013 Analytical Testing Laboratory www.atl.semtechsolutions.com Scanning Electron

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Losartan Potassium and Hydrochlorothiazide Tablets 100 mg/12.5 mg Lupin Limited Goa 403 722

More information

GMP/Regulatory Environment in the

GMP/Regulatory Environment in the GMP/Regulatory Environment in the Latin America Irene Ortiz Barreal, Pharm. D., R.Ph. Pfizer International Affiliate Quality Compliance Regional Leader Latin America/Caribbean April 14, 2011 Discloser

More information

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals

More information

Pharmacy Technician Training Program. Minimum Competencies

Pharmacy Technician Training Program. Minimum Competencies 1. Pharmacy Practice Pharmacy Technician Training Program Minimum Competencies 1.1 The candidate shall be familiar with the mission of pharmacy and the various permitted pharmacy practice sites. The candidate

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Changes to an Approved NDA or ANDA U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) April 2004 CMC Revision

More information

NEUROTONE THR 00904/0005 UKPAR

NEUROTONE THR 00904/0005 UKPAR NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet

More information

The Use of Mean Kinetic Temperature (MKT) in the Handling, Storage, and Distribution of Temperature Sensitive Pharmaceuticals

The Use of Mean Kinetic Temperature (MKT) in the Handling, Storage, and Distribution of Temperature Sensitive Pharmaceuticals The Use of Mean Kinetic Temperature (MKT) in the Handling, Storage, and Distribution of Temperature Sensitive Pharmaceuticals Robert H. Seevers, Ph.D., Jeffrey Hofer, & Paul Harber Eli Lilly and Company

More information

Reconstitution of Solutions

Reconstitution of Solutions Chapter 12 Reconstitution of Solutions Reconstitution Process of mixing and diluting solutions Some medications supplied in powder form and must be mixed with liquid before administration Parts of Solutions

More information

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC. Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval

More information

Quality by Design (QbD) Overview

Quality by Design (QbD) Overview Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System

More information

Tableting Punch Performance Can Be Improved With Precision Coatings

Tableting Punch Performance Can Be Improved With Precision Coatings Tableting Punch Performance Can Be Improved With Precision Coatings by Arnold H. Deutchman, Ph. D. Director of Research and Development (614) 873-4529 X 114 adeutchman@beamalloy.net Mr. Dale C. Natoli

More information

Laboratory 5: Properties of Enzymes

Laboratory 5: Properties of Enzymes Laboratory 5: Properties of Enzymes Technical Objectives 1. Accurately measure and transfer solutions with pipettes 2. Use a Spectrophotometer to study enzyme action. 3. Properly graph a set of data. Knowledge

More information

Global Lab Capabilities Pharma Biotech

Global Lab Capabilities Pharma Biotech Global Lab Capabilities Pharma Biotech NSF Health Sciences global network of laboratories delivers expert solutions to pharmaceutical, biotechnology and medical device companies in the areas of analytical

More information

Annex 9 Guidelines on packaging for pharmaceutical products

Annex 9 Guidelines on packaging for pharmaceutical products World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 9 Guidelines on packaging for pharmaceutical products Introductory note 120 Glossary 121 1. Aspects of packaging 125 1.1 General

More information

: Sharpie King Size Permanent Markers. 3500 Lacey Road, 10th Floor Downers Grove, IL 60515 USA 800-323-0749 or 630-829-2500

: Sharpie King Size Permanent Markers. 3500 Lacey Road, 10th Floor Downers Grove, IL 60515 USA 800-323-0749 or 630-829-2500 PRODUCT DATA SHEET Section 1. Identification Product name : Sharpie King Size Permanent Markers Material uses : Writing instruments Manufacturer : Newell Brands 3500 Lacey Road, 10th Floor Downers Grove,

More information

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use.

BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. BRIEFING 661.2 Plastic Packaging Systems for Pharmaceutical Use. USP proposes the revision and development of a suite of plastic packaging system standards in the current issue of PF. General test chapter

More information

Guideline for Industry

Guideline for Industry Guideline for Industry Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products July 1996 ICH Q5C Table of Contents I. INTRODUCTION (1)... 1 II. SCOPE OF THE ANNEX

More information